If Your AI Can’t Explain Itself, Can FDA Authorize It?

Why It Matters

Without explainable AI, FDA clearance is unlikely, delaying market entry and increasing compliance costs for medtech firms. Clear documentation also protects clinicians and patients by ensuring safe, accountable use of AI diagnostics.

Key Takeaways

• FDA now requires traceability of data, features, and model versions
• Human‑oversight plans must define clinician actions on AI outputs
• Subgroup performance and bias analysis are mandatory for approval
• Explainability documentation must be integrated into the QMS from day one

Pulse Analysis

The FDA’s regulatory stance on AI‑enabled Software as a Medical Device (SaMD) has evolved from a pure performance focus to a comprehensive explainability mandate. While a 99% sensitivity score once sufficed for 510(k) clearance, reviewers now demand a transparent chain of custody that links each output to its training data, preprocessing steps, and design decisions. This shift is anchored in the 2021 Good Machine Learning Practice (GMLP) principles, which make purpose, assumptions, and limitations explicit, and the 2025 Predetermined Change Control Plan (PCCP) requirements that enable post‑market model updates without a new submission. Together with the IMDRF N41 clinical evaluation framework, these documents form an implicit explainability standard that manufacturers must meet.

Three pillars underpin the FDA’s expectations: traceability, accountability, and comprehensibility. Traceability obliges developers to document dataset demographics, feature selection, and version history, allowing reviewers to reproduce and scrutinize model behavior. Accountability defines the human‑oversight model, clarifying who intervenes when the AI errs and how performance is monitored in real‑world settings. Comprehensibility ensures that clinicians—radiologists, nurses, or primary‑care physicians—receive outputs that are clinically interpretable, with confidence levels and clear limitation statements, without needing to understand the algorithm’s internal math. These requirements are reinforced by the 2026 Quality Management System Regulation, which integrates explainability artifacts into the broader ISO 13485‑aligned QMS.

For medtech companies, embedding transparency early in the development lifecycle is no longer optional. A well‑crafted Algorithm Description Document, complete with demographic breakdowns, subgroup performance, and post‑market surveillance plans, can shave months off the remediation cycle and smooth the path to De Novo or 510(k) clearance. Firms that treat explainability as a core design principle not only accelerate regulatory approval but also build clinician trust, reduce liability, and position their AI products for sustainable market adoption. The era of black‑box AI with strong metrics alone is over; accountable, understandable algorithms are now the prerequisite for FDA authorization.